Hôpital Saint-Antoine
Paris, 75012, France
Location status: Recruiting
Location contact
Alexandre CHALLINE, MD, PhD
CONTACT
01 49 28 25 33 ext. +33
Christelle AUGER
CONTACT
01 71 76 07 53 ext. +33
NCT Number: NCT06768164
The treatment of a local distal gastric cancer remains surgical before or after chemotherapy. Partial gastrectomy is recommended for distal location cancer The recommendations for restoring continuity are less evident. There are two main techniques: the Roux-En-Y (REY) requiring 2 anastomoses (gastro-jejunostomy and entero-enterostomy) and the Billroth 2 (B2) with a single anastomosis (gastro-jejunostomy). The choice remains matter of debate.
There was no difference on the global health status score from the QLQ-C30 questionnaire. However, the health-related quality of life (HRQoL) was significantly improved only in the REY group between pre- and post-gastrectomy. A significant difference for endoscopic gastritis in favor of the REY group was reported.
The purpose of this study is to determine which surgical technique improve the health related quality of life after distal gastrectomy.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 3
Paris, 75012, France
Location status: Recruiting
Alexandre CHALLINE, MD, PhD
CONTACT
01 49 28 25 33 ext. +33
Christelle AUGER
CONTACT
01 71 76 07 53 ext. +33
The realization of REY suggests an improvement of the HRQoL after distal gastric resection in comparison to the B2 anastomosis justifying the need of a RCT on the topic. Moreover, the REY could improve the gastro-intestinal symptoms and gastritis. The investigators hypothesize that the REY intervention after distal gastrectomy will improve HRQoL for 3 targeted dimensions of the EORTC QLQ-OG25 questionnaire (eating, reflux, pain and discomfort) in patients with gastric cancer.
All patients with a distal gastric cancer treated in curative intent by surgery with distal gastrectomy should be included. The choice of this population belongs in the fact that no reconstruction according billroth2 are performed for other gastric cancer requiring a total gastrectomy. Therefore, all patients treated by total gastrectomy need to be excluded. Secondly, the increase in survival of this population in the past decade araising to 75% at 5 years allows investigators to question the quality of life after surgery.
The anastomosis is realized with the proximal jejunum without entero-enterostomy in the first 70 cm after the angle of Treitz. The gastrojejunostomy could be ante-colic or trans-mesocolic. The anastomosis could be performed according the surgeon decision (mechanical or handsewn, isoperistaltic or anisoperistaltic).
The length of jejunum of the Y section needs to be at least 60 cm. The Roux-en-Y anastomosis could be antecolic or transmesocolic. The anastomosis could be realized according the surgeon decision (mechanical or handsewn, isoperistaltic or anisoperistaltic).
The choice between these two techniques will not add an increased risk to the patient since they are both recommended by national guidelines, they are both performed as standard care and there is no difference in Quality of Life at long term.
During surgery:
Interventions added for the research are:
Expected benefits for the participants: Improve HRQoL after distal gastrectomy. Patients will not be exposed to a specific risk as the two methods of reconstruction are described and used in the routine.
The design of the study (without excessive invasive exam) and the routine care monitoring associated to a better HRQoL evaluation compared to the "classic" post-operative follow-up of patient will help patient decision to participate to the study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
B2 technique requires a single anastomosis (gastro-jejunostomy) after distal gastrectomy
REY technique requires 2 anastomoses (gastro-jejunostomy and entero-enterostomy) after distal gastrectomy
Time frame: One year post-surgery
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, OesophagoGastric 25 (EORTC QLQ-OG25) at 1 year post surgery with 3 targeted dimensions : eating, reflux, pain and discomfort. Health-related Quality of life (HRQoL) will be considered as being improved in one arm if at least one of the 3 targeted dimensions is significantly improved without a significantly deterioration for the other 2 targeted dimensions :
Time frame: Baseline, 3 months, 6 months, 1 year and 2 years post-surgery
Other dimensions of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, OesophagoGastric 25 (EORTC QLQ-OG25) questionnaire :
Time frame: Baseline, 3 months, 6 months, 1 year and 2 years post-surgery
Other dimensions of the HRQoL measured with the EORTC QLQ-C30 ( European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaires, Core 30) questionnaire will be described at baseline, 3 months, 6 months, 1 year and 2 years post-surgery :
Time frame: The long-term HRQoL (EORTC QLQ-OG25 questionnaire) after surgery for gastric cancer at 2 years
Time frame: et The long-term HRQoL (EORTC QLQ-C30 questionnaire) after surgery for gastric cancer at 2 years
The long-Term HRQoL after surgery for gastric cancer at 2 years
Time frame: 2 years post-surgery
The long-term HRQoL after surgery for gastric cancer at 2 years (EORTC QLQ-C30 )
Time frame: 2 years post-surgery
The long-term HRQoL after surgery for gastric cancer at 2 years (EORTC QLQ-OG25)
Time frame: 90 days post-surgery
The postoperative morbidity at 90 days will be measured with the several following complications: Surgical site infection / leakage, gastroparesis, gastro-intestinal occlusion, stasis syndrome, dumping syndrome, ulcerative pathology
Time frame: 1 year post-surgery
The postoperative morbidity at 1 year post surgery will be measured with the several following complications: Surgical site infection / leakage, gastroparesis, gastro-intestinal occlusion, stasis syndrome, dumping syndrome, ulcerative pathology
Time frame: 1 year post-surgery
The biliary reflux and gastritis will be assessed by endoscopy at 1 year post-surgery
Time frame: 3 months, 6 months, 1 year and 2 years post-surgery
The use of PPI will be measured by taking PPI in the past week at 3 months, 6 months, 1 year and 2 years post-surgery
Time frame: 1 year post-surgery
The survival at 1 year post-surgery will be recorded by OS and DFS rate. DFS, defined as the time from surgery and locoregional recurrence, occurrence of distant metastases or second gastric cancer, or death (all causes) or the date of the last follow-up, at which point data will be censored.
OS, defined as the time from surgery to the death from any cause or the date of the last follow-up, at which point data will be censored.
Time frame: 2 years post-surgery
The survival at 2 years post-surgery will be recorded by OS and DFS rate. DFS, defined as the time from surgery and locoregional recurrence, occurrence of distant metastases or second gastric cancer, or death (all causes) or the date of the last follow-up, at which point data will be censored.
OS, defined as the time from surgery to the death from any cause or the date of the last follow-up, at which point data will be censored.
Contact information is provided by the study sponsor or research team.
Alexandre CHALLINE, MD, PhD
CONTACT
Christelle AUGER
CONTACT
Assistance Publique - Hôpitaux de Paris
Other
Health-Related Quality Of Life After Partial Gastrectomy for Gastric Cancer: Comparison of Reconstruction by Billroth II or Roux-en-Y. A Randomized, Comparative, Multicentric, Single-blinded Study
Acronym: BYQoL-GC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07000253
Digestive System Diseases, Digestive System Neoplasms
Amsterdam, Netherlands
View Trial DetailsNCT06028737
Advanced Gastric Adenocarcinoma, Advanced Gastric Carcinoma
Vilnius, Lithuania
View Trial DetailsNCT06702683
Digestive System Diseases, Digestive System Neoplasms
Nanjing, Jiangsu, China
View Trial DetailsNCT07018063
Digestive System Diseases, Digestive System Neoplasms
Beijing, Beijing Municipality, China
View Trial Details